Privia Health Group (PRVA) director Jaewon Ryu granted 8,463 restricted stock units

Rhea-AI Filing Summary

Ryu Jaewon reported acquisition or exercise transactions in this Form 4 filing.

Privia Health Group director Jaewon Ryu received an equity grant in the form of restricted stock units. On the reported date, he was awarded 8,463 RSUs under the company’s 2021 Omnibus Incentive Plan at no cash cost to him. These RSUs will vest on the earlier of the day immediately preceding Privia’s 2027 annual stockholders’ meeting or the first anniversary of the grant date. Following this award, Ryu directly holds 47,110 shares of Privia common stock, reflecting his ongoing equity-based alignment with the company’s performance.

Insights

Equity compensation analyst

Routine director RSU grant that increases equity alignment but is not a market buy.

Director Jaewon Ryu received 8,463 restricted stock units under Privia Health Group’s 2021 Omnibus Incentive Plan, with a reported price of $0.00 per unit. This indicates a standard compensation award rather than an open-market purchase.

The RSUs vest on the earlier of the day before the company’s 2027 annual meeting or the first anniversary of grant, so value depends on continued service and future share price. After this award, Ryu directly holds 47,110 shares, showing a meaningful but not unusually large equity position.

This type of grant is common for directors of public companies and generally viewed as routine governance practice. It does not signal a discretionary buy or sell decision, so the informational value for near-term stock expectations is limited.

Insider Trade Summary

Net Buyer: 8,463 shares

Net Buy 1 txn

Insider Ryu Jaewon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value per share	8,463	$0.00	$0.00

Holdings After Transaction: Common Stock, $0.01 par value per share — 47,110 shares (Direct)

Footnotes (1)

1. F1. On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant.

Key Figures

RSU grant size: 8,463 units Grant price: $0.00 per unit Shares held after: 47,110 shares +1 more

4 metrics

RSU grant size 8,463 units Restricted stock units awarded to director on May 20, 2026

Grant price $0.00 per unit Reported transaction price for RSU award

Shares held after 47,110 shares Director’s direct common stock holdings following the award

Vesting trigger Earlier of 2027 meeting minus one day or 1-year anniversary RSU vesting condition from footnote F1

Key Terms

restricted stock units, 2021 Omnibus Incentive Plan, Grant, award, or other acquisition, annual meeting of stockholders

4 terms

restricted stock units financial

"the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2021 Omnibus Incentive Plan financial

"received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

annual meeting of stockholders financial

"will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/22/2026 - 08:24 AM Learn about SEC filing dates

FAQ

What did Privia Health Group (PRVA) director Jaewon Ryu receive in this Form 4 filing?

Director Jaewon Ryu received 8,463 restricted stock units as an equity award. The grant was made under Privia Health Group’s 2021 Omnibus Incentive Plan and reported with a per-unit price of $0.00, reflecting compensation rather than an open-market stock purchase.

When do Jaewon Ryu’s 8,463 restricted stock units in Privia Health Group (PRVA) vest?

The 8,463 restricted stock units will vest on the earlier of two dates. Vesting occurs either the day immediately before Privia Health Group’s 2027 annual stockholders’ meeting or on the first anniversary of the grant date, depending on which event happens first.

How many Privia Health Group (PRVA) shares does Jaewon Ryu hold after this RSU grant?

After the reported equity award, Jaewon Ryu directly holds 47,110 shares of Privia Health Group common stock. This figure reflects his position following the grant of 8,463 restricted stock units, as disclosed in the Form 4 insider transaction report.

Was Jaewon Ryu’s Privia Health Group (PRVA) transaction a stock purchase or a compensation award?

The transaction was a compensation-related award, not a market purchase. The Form 4 uses code “A” for a grant or award, with 8,463 restricted stock units issued at a reported price of $0.00 per share under the company’s 2021 Omnibus Incentive Plan.

What is the significance of the 2021 Omnibus Incentive Plan for Privia Health Group (PRVA)?

The 2021 Omnibus Incentive Plan is the program under which Privia grants equity awards such as RSUs. Jaewon Ryu’s 8,463-unit award was issued from this plan, highlighting how the company uses stock-based compensation to align director interests with long-term shareholder value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryu Jaewon

(Last) (First) (Middle)

PRIVIA HEALTH GROUP, INC.

950 N. GLEBE ROAD, SUITE 700

(Street)

ARLINGTON VIRGINIA 22203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Privia Health Group, Inc. [ PRVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value per share	05/20/2026		A		8,463(1)	A	$0	47,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On May 20, 2026, the reporting person received 8,463 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2027 annual meeting of stockholders and (ii) the first anniversary of the date of the grant.

Remarks:

	/s/ Anita Beth Adams, as attorney-in-fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)